Abstract
We compared the frequencies of genotypes and alleles of the C3435T and C1236T polymorphisms of the multidrug resistance gene (ABCB1) among adolescents of the indigenous populations of North Asia: Tofalars, Evenks, Soyots. The sample included 86 people (Tofalars—26 people, Evenks—38, Soyots—22). The average age was 14 [12.5–15.5] years for Soyots, 13 [11–15] years for Evenks, and 12 [11.5–15] years for Tofalars. We used real-time polymerase chain reaction (RT-PCR) to identify ABCB1 genotypes. CC genotype C3435T and CC genotype C1236T of the ABCB1 gene could be the cause of drug resistance. The frequency of CC genotype C3435T was 31.82, 18.42, and 15.38% in Soyots, Evenks, and Tofalars, respectively. The frequency of the C allele C3435T of the ABCB1 gene in Soyots, Evenks, and Tofalars was 0.59, 0.46, and 0.52, respectively. The frequency of CC genotype C1236T of the ABCB1 gene was 22.73, 18.42, and 7.69% in Soyots, Evenks, and Tofalars, respectively. The frequency of the C allele of the C1236T polymorphism of the ABCB1 gene was 0.55, 0.58, and 0.54 in Soyots, Evenks, and Tofalars, respectively. Identifying gene variants is important for predicting drug susceptibility. We revealed the similarity of the frequencies of genotypes and alleles of the C3435T and C1236T ABCB1 gene in the indigenous peoples of North Asia to other populations around the world. This allows the use of clinical guidelines for drugs transported by the P-gp system.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Sharom, F.J., ABC multidrug transporters: structure, function and role in chemoresistance, Pharmacogenomics, 2008, vol. 9, no. 1, pp. 105—127. https://doi.org/10.2217/14622416.9.1.105
Sarginson, J.E., Lazzeroni, L.C., Ryan, H.S., et al., ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression, Pharmacogenet. Genomics, 2010, vol. 20, no. 8, pp. 467—475. https://doi.org/10.1097/FPC.0b013e32833b593a
Sun, J., He, Z.G., Cheng, G., et al., Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction, Med. Sci. Monit., 2004, vol. 10, no. 1, pp. RA5—RA14.
Marques, P., Courand, P.Y., Gouin-Thibault, I., et al., P-glycoprotein influences urinary excretion of aldosterone in healthy individuals, J. Hypertens., 2019, vol. 37, no. 11, pp. 2225—2231. https://doi.org/10.1097/HJH.0000000000002150
Gameiro, M., Silva, R., Rocha-Pereira, C., et al., Cellular models and in vitro assays for the screening of modulators of P-gp, MRP1 and BCRP, Molecules, 2017, vol. 22, no. 4, p. 600. https://doi.org/10.3390/molecules22040600
Yakusheva, E.N., Chernykh, I.V., and Biryukova, A.S., Characteristic of P-glycoprotein as a drug peptide transporter, Ross. Med.-Biol. Vestn. im. akad. I.P. Pavlova, 2011, no. 3, pp. 142—146.
Callaghan, R., Berridge, G., Ferry, D.R., and Higgins, C.F., The functional purification of P-glycoprotein is dependent on maintenance of a lipid—protein interface, Biochim. Biophys. Acta, 1997, vol. 1328, no. 2, p. 109. https://doi.org/10.1016/s0005-2736(97)00079-5
https://www.genecards.org/cgi-bin/carddisp.pl?gene= ABCB1&keywords=ABCB1.
Ahmed, S.S., Husain, R.A., Kumar, S., and Ramakrishnan, V., Association between MDR1 gene polymorphisms and Parkinson’s disease in Asian and Caucasian populations: a meta-analysis, J. Neurol. Sci., 2016, vol. 368, pp. 255—262. https://doi.org/10.1016/j.jns.2016.07.041
Wang, J., Wang, B., Bi, J., et al., MDR1 gene C3435T polymorphism and cancer risk: a meta-analysis of 34 case—control studies, J. Cancer Res. Clin. Oncol., 2012, vol. 138, no. 6, pp. 979—989. https://doi.org/10.1007/s00432-012-1171-9
Zaorska, K., Zawierucha, P., Świerczewska, M., et al., Prediction of steroid resistance and steroid dependence in nephrotic syndrome children, J. Transl. Med., 2021, vol. 19, no. 1, pp. 1—13. https://doi.org/10.1186/s12967-021-02790-w
Bossennec, M., Di Roio, A., Caux, C., and Ménétrier-Caux, C., MDR1 in immunity: friend or foe?, OncoImmunology, 2018, vol. 7, no. 12. e1499388. https://doi.org/10.1080/2162402X.2018.1499388
Marzolini, C., Paus, E., Buclin, T., and Kim, R.B., Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance, Clin. Pharmacol. Ther., 2004, vol. 75, no. 1, pp. 13—33. https://doi.org/10.1016/j.clpt.2003.09.012
Hemauer, S.J., Nanovskaya, T.N., Abdel-Rahman, S.Z., et al., Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms, Biochem. Pharmacol., 2010, vol. 79, no. 6, pp. 921—925. https://doi.org/10.1016/j.bcp.2009.10.026
Wang, D., Johnson, A.D., Papp, A.C., et al., Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability, Pharmacogenet. Genomics, 2005, vol. 15, no. 10, pp. 693—704. https://doi.org/10.1097/01.fpc.0000178311.02878.83
Jiang, Z.P., Wang, Y.R., Xu, P., et al., Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics, Basic Clin. Pharmacol. Toxicol., 2008, vol. 103, no. 5, pp. 433—444. https://doi.org/10.1111/j.1742-7843.2008.00300.x
Qiu, F., He, X.J., Sun, Y.X., et al., Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients, Pharmacol. Rep., 2011, vol. 63, no. 3, pp. 815—825. https://doi.org/10.1016/s1734-1140(11)70594-1
Haufroid, V., Mourad, M., Van Kerckhove, V., et al., The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients, Pharmacogenetics, 2004, vol. 14, no. 3, pp. 147—154. https://doi.org/10.1097/00008571-200403000-00002
Dickens, D., Owen, A., Alfirevic, A., and Pirmohamed, M., ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein, Pharmacogenet. Genomics, 2013, vol. 23, no. 6, pp. 314—323. https://doi.org/10.1097/FPC.0b013e328360d10c
Antonio-Andrés, G., Rangel-Santiago, J., Tirado-Rodríguez, B., et al., Role of Yin Yang-1 (YY1) in the transcription regulation of the multi-drug resistance (MDR1) gene, Leuk. Lymphoma, 2018, vol. 59, no. 11, pp. 2628—2638. https://doi.org/10.1080/10428194.2018.1448083
Kimchi-Sarfaty, C., Oh, J.M., Kim, I.W., et al., A “silent” polymorphism in the MDR1 gene changes substrate specificity, Science, 2007, vol. 315, no. 5811, pp. 525—528. https://doi.org/10.1126/science.1135308
Hung, C.C., Chen, C.C., Lin, C.J., and Liou, H.H., Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs, Pharmacogenet. Genomics, 2008, vol. 18, no. 5, pp. 390—402. https://doi.org/10.1097/FPC.0b013e3282f85e36
Ameyaw, M.M., Regateiro, F., Li, T., et al., MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity, Pharmacogenetics, 2001, vol. 11, no. 3, pp. 217—221. https://doi.org/10.1097/00008571-200104000-00005
Mirzaev, K.B., Fedorinov, D.S., Ivashchenko, D.V., and Sychev, D.A., ADME pharmacogenetics: future outlook for Russia, Pharmacogenomics, 2019, vol. 20, no. 11, pp. 847—865. https://doi.org/10.2217/pgs-2019-0013
Pels, Y.R., Marusin, A.V., Spiridonova, M.G., and Stepanov, V.A., Polymorphism of the human MDR1 gene in Siberian and Central Asian populations, Mol. Biol., 2007, vol. 41, no. 6, pp. 894—900. https://doi.org/10.1134/S0026893307060040
Ignat’ev, I.V., MDR1 gene polymorphism: population and pharmacogenetic aspects, Cand. Sci. (Biol.) Dissertation, Moscow: Scientific Center for Biomedical Technologies of the Russian Academy of Medical Sciences, 2007.
Sychev, D.A., Shuev, G.N., Suleymanov, S.S., et al., Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations, Pharmgenomics Pers. Med., 2017, vol. 10, pp. 93—99. https://doi.org/10.2147/pgpm.s129665
Tuychibaeva, N.M., Karimov, Kh.Ya., Alimkhodjaeva, P.R., et al., ABCB1 gene C3435T and C1236T polymorphisms among patients with pharmacoresistant epilepsy and healthy individuals, Int. J. BioMed., 2014, vol. 4, no. 4, pp. 209—212.
Gol’tsova, T.V. and Osipova, L.P., Genetic demography structure of aborigine Siberian populations in connection with issues of microevolution, Inf. Vestn. Vavilovskogo O-va. Genet. Sel., 2006, vol. 10, no. 1, pp. 126—154.
Soroko, E.L., Ethnically mixed married couples in the Russian Federation, Demograf. Obozr., 2014, vol. 1, no. 4, pp. 96—123.
Robertson, A., Selection for heterozygotes in small populations, Genetics, 1962, vol. 47, no. 9, pp. 1291—1300.
http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=7:87508829-87509829.
Bairova, T.A., Ershova, O.A., Kolesnikov, S.I., and Kolesnikova, L.I., Frequencies polymorphism of Q192R of the paraoxonase 1 gene of different ethnic groups of Eastern Siberia, Yakut. Med. J., 2020, no. 3, pp. 70—73. https://doi.org/10.25789/YMJ.2020.71.19
Sambyalova, A.Y., Bairova, T.A., Belyaeva, E.V., et al., CYP2C9, CYP4F2, VKORC1 gene polymorphism in Buryat population, Russ. J. Genet., 2020, vol. 56, no. 12, pp. 1496—1503. https://doi.org/10.1134/S1022795420120121
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest. The authors declare that they have no conflicts of interest.
Statement of compliance with standards of research involving humans as subjects. In working with adolescents, the ethical principles set forth by the World Medical Association Declaration of Helsinki of 1964, revised in 2013 (amended at the 64th General Assembly of the WMA, Brazil), were observed. All study participants were informed about the scientific direction of the study and gave their consent to participate in joint work.
Rights and permissions
About this article
Cite this article
Bairova, T.A., Nemchinova, N.V., Belyaeva, E.V. et al. The Prevalence of Polymorphic Variants of ABCB1 Gene among Indigenous Populations of Siberia. Russ J Genet 58, 57–64 (2022). https://doi.org/10.1134/S1022795421110028
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1022795421110028